Metsera (NASDAQ:MTSR) Earns Outperform Rating from Analysts at Evercore ISI

Equities research analysts at Evercore ISI started coverage on shares of Metsera (NASDAQ:MTSR) in a research report issued on Tuesday,Benzinga reports. The brokerage set an “outperform” rating on the stock.

Metsera Stock Down 5.8 %

Shares of MTSR stock opened at $29.81 on Tuesday. Metsera has a 52 week low of $25.06 and a 52 week high of $32.81.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.